Strengthening Competitiveness of the Autoimmune Disease Portfolio in the Global Market
Celltrion will participate in the 2025 United European Gastroenterology Week (UEGW), which will be held in Berlin, Germany from October 4 to 7 (local time), to showcase the competitiveness and excellence of its autoimmune disease treatment portfolio, including CT-P13 SC (Remsima SC).
UEGW is the largest gastroenterology congress in Europe, where researchers and companies from around the world share the latest research findings and drug development trends for gastrointestinal diseases such as inflammatory bowel disease (IBD) and gastric cancer.
Celltrion will set up an exclusive booth in the main hall of the event and conduct various academic and marketing activities, including two expert sessions for local healthcare professionals and attendees. The sessions will present the latest clinical results, including real-world data on both intravenous (IV) and subcutaneous (SC) formulations of the autoimmune disease treatment Remsima.
On the third day of the congress, Celltrion will hold a symposium titled "Comparison of IV and SC Formulations in Maintenance Therapy for Inflammatory Bowel Disease: When and for Whom Should They Be Administered?" to discuss strategies for switching from effective IV formulations to SC formulations in patients with inflammatory bowel disease.
On the final day, Celltrion will introduce the results of a post-hoc analysis from a global phase 3 maintenance study of CT-P13 SC, which was conducted for two years in patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), through an oral poster presentation.
The study confirmed that patients who lost response to the drug exhibited distinctive baseline characteristics and clinical response patterns from the beginning of treatment compared to those who maintained response for up to two years. This suggests the possibility of identifying predictors of response loss at the initiation of treatment or during the early phase of CT-P13 SC maintenance therapy.
Celltrion expects that the research data presented at this event will further increase the confidence of healthcare professionals and patients in CT-P13 SC. CT-P13 SC is the only subcutaneous formulation of infliximab developed and approved by Celltrion. With its advantages in dosing convenience and therapeutic efficacy, it continues to see rapid prescription growth, especially in Europe and the United States.
In addition, Celltrion plans to highlight the strengths of its major autoimmune disease products at the booth, including the competitiveness of Yuflyma (ingredient: adalimumab), which has recently been rapidly expanding its market share in Europe. According to the market research firm IQVIA, Yuflyma recorded a 24% market share in Europe in the first quarter of this year, up 3 percentage points from the previous quarter, and the gap with the top product is only 1 percentage point.
A Celltrion official said, "We have consistently promoted the excellence of CT-P13 SC at global congresses and have confirmed positive responses from healthcare professionals. We expect favorable reviews at this UEGW as well. We will do our best to increase prescriptions and expand market share by strengthening the competitiveness of our autoimmune disease treatment portfolio."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
